Oric Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 79 to 82.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or better RS Rating as they begin their biggest climbs.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to form a base and break out.
Oric Pharmaceuticals showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
The company holds the No. 247 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
